Skip to content
10-K

Annual Report

Forte Biosciences, Inc. FBRX

0000950170-25-046749

← back to feed
Filed
Mar 28, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 24, 2025 6.58M sh
Capex FY 2024 · Dec 31, 2023 $88K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$28.71M
Cash And Equivalents FY 2024 · Dec 31, 2023 $37.13M
Current Liabilities FY 2024 · Dec 31, 2023 $3.67M
Current Assets FY 2024 · Dec 31, 2023 $38.33M
Total Assets FY 2024 · Dec 31, 2023 $38.98M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$24.92
Eps Basic restated FY 2024 · Dec 31, 2023 −$24.92
Sga Expense FY 2024 · Dec 31, 2023 $10.62M
Net Income FY 2024 · Dec 31, 2023 −$31.48M
Operating Income FY 2024 · Dec 31, 2023 −$32.49M
Stockholders Equity FY 2024 · Dec 31, 2022 $38.82M